AU711634B2 - Compositions having antiviral properties and preparation process - Google Patents
Compositions having antiviral properties and preparation process Download PDFInfo
- Publication number
- AU711634B2 AU711634B2 AU48340/96A AU4834096A AU711634B2 AU 711634 B2 AU711634 B2 AU 711634B2 AU 48340/96 A AU48340/96 A AU 48340/96A AU 4834096 A AU4834096 A AU 4834096A AU 711634 B2 AU711634 B2 AU 711634B2
- Authority
- AU
- Australia
- Prior art keywords
- composition
- composition according
- extract
- coconut
- retrovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims description 80
- 230000000840 anti-viral effect Effects 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 31
- 241000700605 Viruses Species 0.000 claims description 27
- 239000000284 extract Substances 0.000 claims description 22
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 19
- 244000060011 Cocos nucifera Species 0.000 claims description 19
- BLKPFVWYBFDTPX-UHFFFAOYSA-N 2-(6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)acetaldehyde Chemical compound C1C2C(C)(C)C1CC=C2CC=O BLKPFVWYBFDTPX-UHFFFAOYSA-N 0.000 claims description 13
- 240000008607 Opuntia megacantha Species 0.000 claims description 13
- 235000002840 Opuntia megacantha Nutrition 0.000 claims description 13
- 235000006538 Opuntia tuna Nutrition 0.000 claims description 13
- 235000008981 Smilax officinalis Nutrition 0.000 claims description 11
- 240000002493 Smilax officinalis Species 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- 240000000528 Ricinus communis Species 0.000 claims description 10
- 235000004443 Ricinus communis Nutrition 0.000 claims description 10
- 241000159165 Spondias Species 0.000 claims description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 10
- 239000011707 mineral Substances 0.000 claims description 10
- 241001430294 unidentified retrovirus Species 0.000 claims description 10
- 241000196324 Embryophyta Species 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 241000208223 Anacardiaceae Species 0.000 claims description 6
- 239000013535 sea water Substances 0.000 claims description 6
- 241000221017 Euphorbiaceae Species 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 240000001439 Opuntia Species 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 230000002879 macerating effect Effects 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000013618 particulate matter Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 150000003841 chloride salts Chemical class 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 12
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 102100034343 Integrase Human genes 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000000798 anti-retroviral effect Effects 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- 241000234435 Lilium Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- 235000011160 magnesium carbonates Nutrition 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical class [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
1. 1- .ii-i--lii.. Field of Invention The present invention is directed generally to compositions having antiviral properties and a process of producing anti-retroviral compounds.
Background Art The struggle against diseases due to retroviruses has mobilised many teams throughout the world to investigate this area. A great deal of research has been directed to fighting against the AIDS (Acquired Immune Deficiency Syndrome) epidemic.
It is known that the agent responsible for AIDS is a retrovirus called HIV (Human Immune Deficiency Virus) according to an English abbreviated form.
The antiviral drugs most used come from nucleosides, including "zidovudine", or AZT, which was the first anti-retroviral drug available. Since then, the emergence of tough mutant viruses has led to a search for new treatments.
15 The present inventor has found that compositions including a mixture of acid and natural products are capable of inactivating, to some extent, the infectious power of HIV.
There is clearly a need for providing new efficient antiviral compositions.
20 Disclosure of the Invention The present invention is directed to a composition for treating retroviruses. the composition comprising acetic acid, extracts of coconut powder, mineral salts solution, extracts of plant families Cactacea, liliaceous, Anacardiaceae and Euphorbiaceae.
25 Preferably, the extracts of coconut powder are obtained from the coconut tree fruit. More preferably, the extracts of coconut are the white grated content of the coconut.
Preferably, the mineral salt solution is selected from the group consisting of sodium, potassium, calcium, magnesium phosphates, chlorides, sulfates, carbonates and bicarbonates.
Preferably, the extract of Cactacea family is an extract from the plant Opuntia. More preferably, the Opuntia is Nopal. Most preferably, the Nopal is green Nopal fruit.
Preferably the extracts of liliaceous in the composition include "sarsaparilla". More preferably, the "sarsaparilla" is the lily like "sarsaparilla" root.
Preferably, the extract of the plant family Anacardiaceae is an extract from Mombin. more preferably, the Mombin is the bark of Mombin.
Preferably, the extract of the plant family Eeuphorbiacea is from the castor oil plant. More preferably, the composition includes the seeds of the castor oil plant, and most preferably, the composition includes seeds that have been roasted and powdered.
In one preferred embodiment, the present invention is directed to a composition including acetic acid, grated coconuts, sea water, green Nopal fruits, "sarsaparilla" root. "Mombin" bark, and roasted and powdered seeds of the castor oil plant.
Preferably. these ingredients are used in the composition in the following proportions:acetic acid from 5 to 10 litres, more preferably from 7 to 8 litres; coconut powder (preferably the white grated content); approximately 15 coconuts: mineral salts solution (preferably sodium, potassium, magnesium.
calcium. phosphates, chlorides, sulphates. carbonates and bicarbonates).
More preferably, sea water: from 3 to 5 litres: 4 litres: Nopal and in particular grated fruits of green Nopal: from 10 to 20 fruits accounting for 1 to 2kg and more preferably 15 fruits, accounting roughly for "sarsaparilla" root: from 500g to 1kg and more preferably about 750g "Mombin" bark from 500g to 1.5kg and more preferably about 1kg roasted and ground seeds of castor oil plant: from 500g to 1.5kg and 25 more preferably about 1kg.
The present invention is further directed to a process of producing an antiviral composition comprising macerating coconut in the presence of acetic acid for 24 hours, boiling the mixture, filtering the boiled and macerated coconut/acid mixture to remove particulate matter, and adding to the filtrate mineral salts and extracts of plant families Cactacea. liliaceous. Anacardiaceae and Euphorbiaceae.
It has been found that the composition of the present invention has an inhibitory effect of HIV-1 "reverse transcriptase" activity which is likely to exceed 90% compared to the activity calculated on the pilot cells. Further. a drop in the cythopathogenic effect of HIV-1 on cells contaminated by the virus and treated with the compositions of the invention is achieved.
The absence of toxicity of these compositions has been demonstrated on the mouse by intraperitoneal injection with physiological pH.
In another aspect, the present invention is directed to a pharmaceutical composition including a composition according to the first aspect of the invention together with a pharmaceutical excipient.
The pharmaceutical compositions of the invention are particularly adapted to prevent and treat AIDS. combined with other drugs if necessary.
The pharmaceutical compositions are preferably administered by injection in solutions or isotonic injectable suspensions with regard to the blood plasma. Dosage requirements will vary according to the patients health.
The quantity of active principle (dry extract) for a man may change from 1 to 500mg a day.
The invention will be illustrated hereafter with an example of composition of great efficiency regarding HIV-1 virus and with results of 15 testings in vitro and in vivo.
Examples Example 1 Preparation of a composition according to the invention.
The white dry grated content of 10 coconuts and 7 to 8 litres of white vinegar or acetic acid were macerated for at least 24 hours.
20 The resulting mixture was then filtered and the following ingredients were added to the filtrate.
solution rich in minerals, eg. sea water 4 litres green grated Nopal (about 15 fruits) bark of "Mombin" 1kg 25 roasted and powdered seeds of castor oil plant 1kg The resulting mixture was boiled for about 1 hour and then filtered.
Example 2 Study of inactivation of HIV-1 with the composition of Example 1.
Experimental Protocol Inactivation of the virus.
A suspension of viral particles in a RPMI 1640 culture (HIV-1 III B, "inverse transcriptase" activity 3.8 x 1 0 cpm/ml) is incubated with the composition of Example 1 hereafter called "the composition", at 4 C for 2 minutes, then at room temperature for 1 hour and finally at 37 0 C for 2 hours. Following the incubation, the mixture was diluted with an added of foetal calf serum first warmed up at 56 0 C for 30 minutes, to 1/10th, 1/20th, 1/40th. 1/100th. 1/200th the original concentration in the RPMI 1640 culture diluted.
P_ iI/ iiil 1 i i i_ __f Infection Samples of 5 x 10 5 MT4 cells (human cells of lymphoid origin changed by human T lymphocyte virus (HTLV-1) are suspended in 2501 of various dilutions of virus-composition mixture.
After one hour of absorption at room temperature, the cells were resuspended at 5 minute intervals and centrifuged. The virus that was not absorbed was removed. The cells were washed twice with RPMII and put in suspension again in the RPNMI medium with a 10% foetal calf serum concentrated at a 2 x 10 5 /ml. The contaminated cells were put in culture in "microtitration" plates (Costar 96 pots) split into 200~l/pot.
Every culture was made at least in duplicate. Cultures were diluted in the same volume of medium after 5 days and then after 8 days of infection.
A number of control cultures were contaminated at the same time that the suspension of virus A was made with the RPfMI medium.
15 Incubations and dilutions of the control culture were strictly made under the same conditions as for the virus treated with the composition.
An additional control was made with the virus preincubated with a 0.15iM NaCI solution.
The production of the virus was estimated from a correct proportioning 20 of "inverse transcriptase" activity, associated with viral particles that the cells released in the medium. The "inverse transcriptase" is also called "reverse transcriptase" or RT in its abbreviated form.
The RT test was made from 65)l of medium, according to the protocol described by Moog et al., in Antiviral Research. 24, (1994), 275-288. The 25 results were expressed in cpm/test (see Table 2).
The cellular viability was estimated by the MTT test described by Moog et al., as abovementioned (see Table The colouring intensity was expressed in milli DO.
Experiment A The HIV production was estimated after contamination of the MT4 cells with virus preincubated with the composition. After 5 to 7 days of contamination the RT values were approximately 699 to 1.538 cpm/test, whereas for floating particles of non-contaminated cultures, the RT values were approximately 1.400 to 2.100 cpm/test. Every culture contaminated with the non treated virus produced virus after 5 to 11 days.
I_ ~II_ Experiment B The production of HIV was estimated after contamination of CEM-SS cells with HIV-LAi.
A suspension of virus B (HIV-1 LAi, "reverse transcriptase" activity 3 x 10" cpm/ml) was incubated with the composition. All other stages are described in the experiment made on MT4 cells.
Under these conditions, cultures contaminated with the pilot virus (not incubated with the composition) produced virus measurable by RT, 11 days after contamination.
In the case of cells contaminated with the virus preincubated with the composition, the RT values were similar to those ones estimated on the floating particles of the uncontaminated cultures'(1,707 to 2,564 cpm/test) after 11 days of contamination.
Experiment C 15 The experimental protocol followed was the same as that described in ,Experiment A. The measurements recorded at 5 days and 7 days after the 9 o contamination indicated that detection of virus replication was low when it has been preincubated with the composition (RT of uncontaminated pilot cells 972-12.192 cpm/test).
Experiment D In order to estimate the production of virus more quickly than in 9* Experiment B. a virus concentration 10 times more potent was used.
After 5 to 8 days, the production of virus appeared to be strongly inhibited when the virus was preincubated with the composition.
25 The absence of effect noted when using 0.15M NaC1 solution suggests that the virus inhibition was specific to the composition.
These results suggest that the HIV-1 virus preincubated with the composition of the invention results in the inactivation of the infectious power of the viral particles.
Example 3 Study of the composition effect of the first example on the "reverse transcriptase" activity of HIV-1.
A suspension of the HIV-1 virus was melted to different dilutions of the composition. The "reverse transcriptase" activity (RT) was determined, in association with the viral particles, as described by Moog et al in the above reference.
The measurements were determined from at least two samples.
The results obtained are found in Table 1.
Increased concentrations of the composition inhibit the RT activity to more than Another series of experiments, the results of which are given in Table 2, confirm this information.
The experiments suggest that the compositions inhibit the "reverse transcriptase" activity of HIV-1 when measured in vitro.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
Chart 1 RT activity (cpm/test) FINAL DILUTION OF COMPOSITION/VIRUS THE SOLUTIONS
AVERAGE
1/21.164 973 783 1/6 759 724 (94%) 688 1/8 2.453 2,664.(80%) 2.875 1/54 6.875 6,412 (50%)1 1/162 10.035 9,128 (29%o) 1,486 11.747 12.364 12.981
S
S S *5 *5*5
S.
pa
S
S *5 S
S
S.
*S
S S a
S
*5 S a 14,318 1.764 743AVERAGE PILOT VIRUS 12 .68 7 12 .218 15,036 The figures in brackets indicate the 06 of inhibition of the RT activity 9 Chart 2 RT activity (cpm/test) FINAL DILUTION OF THE SOLUTIONS COMPOSITION/VIRUS1
S
0 S. *5
S
S
S*
C
5 0 *5 4**e *5*S
S
S
.5 *5*S S S
SO
*5 S S
S
55 S. 50 S S S. S
SO
55
S
AVERAGE
1/2 550 666 (100%)- /4 925 724 (100%) 524 1/8 572 507 (100%) 1/6910 854 (100%) 797 13227.045 28,790 (820%) 30.5 1/455.180 63.265 75.351 1/128 108.652 106.163 103,6 73 1/25 6 129 .555 10 7.540 18,548 (24%o) 1 4 1/512 1.024 167.936 156,267 The figures in brackets indicate the of inhibition of the RT activity
Claims (24)
1. A composition for the treatment of a virus or retrovirus, comprising acetic acid; extract of coconut: mineral salts; and extracts from each of the plant families Cactacea, liliaceous, Anacardiaceae and Euphorbiaceae.
2. The composition according to claim 1, wherein extract of coconut is the grated white content of the coconut.
3. The composition according to claim 1 or 2 wherein the mineral salts are selected from the group consisting of sodium, potassium, calcium, magnesium, phosphates, chlorides, sulphates, carbonates and bicarbonates.
4. The composition according to any one of claims 1 to 3, wherein extract :of plant family Cactacea is an extract from the plant Opuntia. 15
5. The composition according to claim 4, wherein Opuntia is a Nopal.
6. The composition according to claim 5, wherein Nopal is a green Nopal fruit.
7. The composition according to any one of claims 1 to 6. wherein the composition further includes an extract from "sarsaparilla". 20
8. The composition according to claim 7, wherein "sarsaparilla" is the lily- like root of "sarsaparilla".
9. The composition according to any one of claims 1 to 8, wherein the extract from the plant family Anacardiaceae is an extract from "Mombin".
10. The composition according to claim 9. wherein "Mombin" is the bark of 25 "Mombin".
11. The composition according to any one of claims 1 to 10, wherein the extract from the plant family Euphorbiaceae is castor oil plant seeds.
12. The composition according to claim 11, wherein the castor oil plant seeds are roasted and powdered.
13. Composition for the treatment of a virus or a retrovirus, wherein the composition comprises acetic acid, grated coconut, sea water, green Nopal fruits, "sarsaparilla" root, "Mombin" bark, powdered and roasted castor oil plant seeds.
14. Composition for the treatment of a virus or a retrovirus. wherein the composition comprises: 5 to 10 litres of acetic acid: grated coconut of 10 coconuts: 3 to 5 litres of mineral salts and sea water; 1 to 2kg of green Nopal fruit; 500g to lkg of "sarsaparilla" root: 500g to 1.5kg of "Monibin" bark; and 500g to 1.5kg of ground and roasted castor oil plant seeds.
The composition according to claim 14 wherein the composition includes 7 to 8 litres of acetic acid.
16. The composition according to any one of claims 14 or 15 wherein the composition includes 4 litres of mineral salts and sea water.
17. The composition according to any one of claims 14 to 16 wherein the composition includes 1.5kg of green Nopal fruit.
18. The composition according to any one of claims 14 to 17 wherein the composition includes 75Og "sarsaparilla" root. 9999'* 15
19. The composition according to any one of claims 14 to 18 wherein the composition includes lkg of "Monibin" bark.
The composition according to any one of claims 14 to 19 wherein the composition includes 1kg of ground and roasted seed of the castor oil plant.
21. A process of producing an antiviral composition comprising: o 20 macerating coconut in the presence of acetic acid for 24 hours to form a S"mixture; boiling the mixture; filtering the boiled and macerated coconut/acid mixture to remove particulate matter, and adding to the filtrate mineral salts and extract from each of plant families SCactacea, liliaceous. Anacardiaceae and Euphorbiaceae
22. Use of the composition as claimed in any one of claims 1 to 20 for the preparation of a medicament for the treatment of a retrovirus.
23. The use according to claim 22 wherein the retrovirus is HIV.
24. A medicament for the treatment of a retrovirus wherein the medicament includes the composition according to any one of claims 1 to 20 together with a pharmaceutical excipient. 12 A method of treating a retrovirus comprising administering to a subject in need of treatment a therapeutically effective amount of the composition as claimed in claim Dated this twentieth day of August 1999 Alix-Roland Commin Patent Attorneys for the Applicant: F B RICE CO 00 0*00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9502595 | 1995-03-06 | ||
| FR9502595A FR2731354B1 (en) | 1995-03-06 | 1995-03-06 | COMPOSITIONS HAVING ANTIVIRAL PROPERTIES AND PROCESS FOR OBTAINING SAME |
| PCT/FR1996/000230 WO1996027383A1 (en) | 1995-03-06 | 1996-02-13 | Compositions having antiviral properties and preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4834096A AU4834096A (en) | 1996-09-23 |
| AU711634B2 true AU711634B2 (en) | 1999-10-21 |
Family
ID=9476780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU48340/96A Ceased AU711634B2 (en) | 1995-03-06 | 1996-02-13 | Compositions having antiviral properties and preparation process |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0768887B1 (en) |
| JP (1) | JPH10506124A (en) |
| AP (1) | AP705A (en) |
| AT (1) | ATE201825T1 (en) |
| AU (1) | AU711634B2 (en) |
| CA (1) | CA2189474C (en) |
| DE (1) | DE69613190T2 (en) |
| DK (1) | DK0768887T3 (en) |
| EA (1) | EA000112B1 (en) |
| ES (1) | ES2171653T3 (en) |
| FR (1) | FR2731354B1 (en) |
| GR (1) | GR3036556T3 (en) |
| OA (1) | OA10332A (en) |
| PT (1) | PT768887E (en) |
| WO (1) | WO1996027383A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000001398A1 (en) * | 1998-07-02 | 2000-01-13 | Nobutho Gladys Makupula | Anti-viral plant extract |
| US6238672B1 (en) | 1999-04-23 | 2001-05-29 | E. Excel International Inc. | Dietary supplements containing dehydrated cactus fruit juice and ginseng berry juice |
| MY124001A (en) * | 1999-04-23 | 2006-06-30 | E Excel Int | Dietary supplements containing dehydrated cactus fruit juice and ginseng berry juice |
| US6524626B2 (en) | 1999-04-23 | 2003-02-25 | E Excel International, Inc. | Ginseng berry topical products |
| US6576286B1 (en) | 1999-04-23 | 2003-06-10 | E Excel International | Cactus fruit drinks and food products |
| US6210738B1 (en) | 1999-04-23 | 2001-04-03 | E Excel Internatioanal Inc. | Freeze-dried ginseng berry tea |
| FR2926465B1 (en) * | 2008-01-17 | 2016-08-12 | Alix Roland Commin | ANTI-VIRAL COMPOSITION, IN PARTICULAR AIDS |
| WO2011010000A1 (en) * | 2009-07-22 | 2011-01-27 | Alix Roland Commin | Antiviral and retroviral composition, in particular for treating aids |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0825890B2 (en) * | 1987-06-18 | 1996-03-13 | 呉羽化学工業株式会社 | Antiviral agent |
| FR2662353A1 (en) * | 1990-05-22 | 1991-11-29 | Neyroud Andre | SOFT BREAD OR LIQUID ANTISEPTIC LIQUID, WHICH KILLS AIDS VIRUSES, PROVIDES BODY HYGIENE AND PROTECTS SKIN. |
| GB9126393D0 (en) * | 1991-12-12 | 1992-02-12 | Skinner Gordon R B | Anti microbial activity from extracts of cactus |
-
1995
- 1995-03-06 FR FR9502595A patent/FR2731354B1/en not_active Expired - Fee Related
-
1996
- 1996-02-13 DE DE69613190T patent/DE69613190T2/en not_active Expired - Fee Related
- 1996-02-13 EA EA199600087A patent/EA000112B1/en not_active IP Right Cessation
- 1996-02-13 PT PT96904129T patent/PT768887E/en unknown
- 1996-02-13 ES ES96904129T patent/ES2171653T3/en not_active Expired - Lifetime
- 1996-02-13 DK DK96904129T patent/DK0768887T3/en active
- 1996-02-13 AT AT96904129T patent/ATE201825T1/en not_active IP Right Cessation
- 1996-02-13 WO PCT/FR1996/000230 patent/WO1996027383A1/en not_active Ceased
- 1996-02-13 AP APAP/P/1996/000872A patent/AP705A/en active
- 1996-02-13 JP JP8526645A patent/JPH10506124A/en not_active Ceased
- 1996-02-13 EP EP96904129A patent/EP0768887B1/en not_active Expired - Lifetime
- 1996-02-13 CA CA002189474A patent/CA2189474C/en not_active Expired - Fee Related
- 1996-02-13 AU AU48340/96A patent/AU711634B2/en not_active Ceased
- 1996-10-25 OA OA60910A patent/OA10332A/en unknown
-
2001
- 2001-09-06 GR GR20010401410T patent/GR3036556T3/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996027383A1 (en) | 1996-09-12 |
| CA2189474A1 (en) | 1996-09-12 |
| DE69613190D1 (en) | 2001-07-12 |
| EA199600087A1 (en) | 1997-09-30 |
| AP9600872A0 (en) | 1996-10-31 |
| OA10332A (en) | 1997-10-07 |
| FR2731354B1 (en) | 1997-05-09 |
| EP0768887B1 (en) | 2001-06-06 |
| GR3036556T3 (en) | 2001-12-31 |
| JPH10506124A (en) | 1998-06-16 |
| DE69613190T2 (en) | 2002-01-31 |
| EA000112B1 (en) | 1998-08-27 |
| EP0768887A1 (en) | 1997-04-23 |
| DK0768887T3 (en) | 2001-09-10 |
| ATE201825T1 (en) | 2001-06-15 |
| CA2189474C (en) | 2003-07-29 |
| AU4834096A (en) | 1996-09-23 |
| ES2171653T3 (en) | 2002-09-16 |
| FR2731354A1 (en) | 1996-09-13 |
| PT768887E (en) | 2001-11-30 |
| AP705A (en) | 1998-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Okwu et al. | Evaluation of the chemical composition of Dacryodes edulis and Raphia hookeri Mann and Wendl exudates used in herbal medicine in south eastern Nigeria | |
| Thakur et al. | Momordica balsamina: a medicinal and neutraceutical plant for health care management | |
| Chakraborty et al. | Garlic (Lahsun)–an immunity booster against SARS-CoV-2 | |
| AU711634B2 (en) | Compositions having antiviral properties and preparation process | |
| JP2001072582A (en) | Functional oral composition | |
| US5980903A (en) | Composition for the treatment of viral infections including HIV | |
| Omodale et al. | Protective effect of aqueous root extract of Gongronema latifolium against paracetamol induced hepatotoxicity and chloroquine induced nephrotoxicity in rats | |
| Madaki et al. | Antioxidant potential of Waltheria Indica methanol leaf extract in Trypanosoma Brucei Brucei infected mice | |
| KR101023487B1 (en) | Arthritis prevention or treatment composition comprising a mixed herbal extract of Schisandra chinensis, golden and thawed skin as an active ingredient | |
| Biswal et al. | Natural products based antibacterial and antiviral materials | |
| KR19990085818A (en) | Antiviral drugs and functional foods with therapeutic and preventive functions of the cold | |
| JPH01238532A (en) | Antiinfectant | |
| AU760967B2 (en) | Herbal composition for the prophylaxis and treatment of AIDS | |
| JP4121957B2 (en) | Indigo preparation and its use in preventing or treating human immunodeficiency virus infection | |
| Sasaki | Bioactive phytocompounds and products traditionally used in Japan | |
| Qin et al. | Molecular Mechanisms of Phyllanthus urinaria in Cerebral Ischemia-Reperfusion Injury | |
| KR100295395B1 (en) | Antiviral pharmaceutical composition useful for prevention and treatment of a cold caused by influenza a virus and a functional food | |
| TWI917190B (en) | Japanese encephalitis virus (jev) infection inhibiting combination with sarcodia sp. extracts and usage thereof | |
| KR100377813B1 (en) | New bamboo extract-containing composition for treatment, and agents comprising the same | |
| CN111840448A (en) | Preparation method and application of anti-chapping compound traditional Chinese medicine liposome | |
| US6582733B1 (en) | Composition for the treatment of hepatitis including HCV | |
| CN116196305B (en) | A composition and its application in preventing and treating lung damage caused by cadmium | |
| KR20030027133A (en) | The Method of Production an Natural Health Food or a Medicine for preventing and curing of Influenza Virus infection as to use Black Elderberry | |
| EP2456452A1 (en) | Antiviral and retroviral composition, in particular for treating aids | |
| KR20010089496A (en) | Preventives for hepatopathy |